These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24951107)

  • 21. Androgen and breast cancer: an update.
    McNamara KM; Sasano H
    Curr Opin Endocrinol Diabetes Obes; 2016 Jun; 23(3):249-56. PubMed ID: 26945136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple-negative breast cancer: role of the androgen receptor.
    Gucalp A; Traina TA
    Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
    Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
    BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
    Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
    Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of androgen and microRNA in triple-negative breast cancer.
    Al-Othman N; Ahram M; Alqaraleh M
    Breast Dis; 2020; 39(1):15-27. PubMed ID: 31839601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
    Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
    Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.
    Feng J; Li L; Zhang N; Liu J; Zhang L; Gao H; Wang G; Li Y; Zhang Y; Li X; Liu D; Lu J; Huang B
    Oncogene; 2017 May; 36(20):2775-2790. PubMed ID: 27893717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights.
    Anestis A; Zoi I; Papavassiliou AG; Karamouzis MV
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31952272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor.
    Casaburi I; Cesario MG; Donà A; Rizza P; Aquila S; Avena P; Lanzino M; Pellegrino M; Vivacqua A; Tucci P; Morelli C; Andò S; Sisci D
    Oncotarget; 2016 Mar; 7(11):12651-61. PubMed ID: 26862856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting Androgen Receptor Signaling in Breast Cancer.
    Dai C; Ellisen LW
    Oncologist; 2023 May; 28(5):383-391. PubMed ID: 36972361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
    Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
    Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas.
    Wang Y; He X; Yu Q; Eng C
    Hum Mol Genet; 2013 Jun; 22(11):2263-72. PubMed ID: 23418309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.
    Salvi S; Bonafè M; Bravaccini S
    Semin Cancer Biol; 2020 Feb; 60():132-137. PubMed ID: 31002873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
    Liu D
    Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.
    Hu T; Zhao G; Liu Y; Long M
    Technol Cancer Res Treat; 2021; 20():15330338211027900. PubMed ID: 34159849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
    Hackenberg R; Schulz KD
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):113-7. PubMed ID: 8603031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consideration of breast cancer subtype in targeting the androgen receptor.
    Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
    Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.